MX2020002683A - Composiciones topicas y metodos de tratamiento. - Google Patents

Composiciones topicas y metodos de tratamiento.

Info

Publication number
MX2020002683A
MX2020002683A MX2020002683A MX2020002683A MX2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A MX 2020002683 A MX2020002683 A MX 2020002683A
Authority
MX
Mexico
Prior art keywords
methods
topical compositions
treatment
endoxifen
hormone
Prior art date
Application number
MX2020002683A
Other languages
English (en)
Inventor
Steven C Quay
Avadhesh S Kushwaha
Edward T Kisak
John M Newsam
Original Assignee
Atossa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atossa Therapeutics Inc filed Critical Atossa Therapeutics Inc
Publication of MX2020002683A publication Critical patent/MX2020002683A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción proporciona composiciones tópicas novedosas que comprenden endoxifeno y sales y solvatos del mismo y métodos para elaborar las composiciones; ciertos compuestos han sido combinados para formar composiciones tópicas estables que comprenden endoxifeno; la presente descripción también proporciona métodos para el tratamiento de trastornos de mama dependientes de hormonas y del tracto reproductivo dependientes de hormonas.
MX2020002683A 2017-09-11 2018-09-10 Composiciones topicas y metodos de tratamiento. MX2020002683A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762556920P 2017-09-11 2017-09-11
US201762556799P 2017-09-11 2017-09-11
US201762556884P 2017-09-11 2017-09-11
US201862624787P 2018-01-31 2018-01-31
US201862693885P 2018-07-03 2018-07-03
PCT/US2018/050197 WO2019051370A1 (en) 2017-09-11 2018-09-10 TOPICAL COMPOSITIONS AND METHODS OF TREATMENT

Publications (1)

Publication Number Publication Date
MX2020002683A true MX2020002683A (es) 2020-09-25

Family

ID=65634433

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002683A MX2020002683A (es) 2017-09-11 2018-09-10 Composiciones topicas y metodos de tratamiento.

Country Status (12)

Country Link
US (2) US20200215006A1 (es)
EP (1) EP3681478B1 (es)
JP (1) JP7376105B2 (es)
KR (1) KR20200051689A (es)
CN (1) CN111212631A (es)
AU (1) AU2018329182A1 (es)
CA (1) CA3074302A1 (es)
IL (1) IL272945A (es)
MX (1) MX2020002683A (es)
SG (1) SG11202001885WA (es)
TW (1) TW201919594A (es)
WO (1) WO2019051370A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL304863B2 (en) 2017-09-11 2025-08-01 Atossa Therapeutics Inc Methods for making and using endoxifen
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1663142A2 (en) * 2003-06-23 2006-06-07 MacroChem Corporation Compositons and methods for topical administration
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
CN102225046A (zh) * 2005-08-05 2011-10-26 努沃研究公司 透皮释药剂型
US20120164075A1 (en) * 2006-11-21 2012-06-28 Jina Pharmaceuticals, Inc. Endoxifen methods and compositions in the treatment of mammalian diseases
DK2101731T3 (en) * 2006-11-21 2018-04-16 Jina Pharmaceuticals Inc ENDOXIFEN FOR USING CANCER TREATMENT
MX337408B (es) * 2007-03-22 2016-03-03 Berg Llc Formulaciones topicas que tienen biodisponibilidad aumentada.
SI3202420T1 (sl) * 2008-12-11 2020-08-31 Besins Healthcare Luxembourg Sarl Transdermalni farmacevtski sestavki, ki obsegajo serm
US20100317635A1 (en) * 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
US9220680B2 (en) * 2012-07-13 2015-12-29 South Dakota State University Compositions and methods for localized drug delivery through mammary papillae
AU2016247674A1 (en) * 2015-04-14 2017-10-19 Atossa Genetics Inc. Compositions and methods of treatment of breast disorders and estrogen-related disorders

Also Published As

Publication number Publication date
AU2018329182A1 (en) 2020-03-19
SG11202001885WA (en) 2020-03-30
JP7376105B2 (ja) 2023-11-08
WO2019051370A1 (en) 2019-03-14
EP3681478B1 (en) 2025-09-10
TW201919594A (zh) 2019-06-01
US20240148675A1 (en) 2024-05-09
EP3681478A4 (en) 2021-07-14
IL272945A (en) 2020-04-30
US20200215006A1 (en) 2020-07-09
CA3074302A1 (en) 2019-03-14
KR20200051689A (ko) 2020-05-13
CN111212631A (zh) 2020-05-29
JP2020533342A (ja) 2020-11-19
EP3681478A1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
CL2019001709A1 (es) Derivados pirazol como inhibidores de malt1.
MX2021001439A (es) Composiciones y metodos para el tratamiento de la disfuncion de la glandula de meibomio.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
MX2018000929A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl.
ECSP17070706A (es) Inhibidores de bromodominio
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
MX2019015888A (es) Bifenil amidas con grupos eter modificados como inhibidores de hsp90 e inductores de hsp70.
MX388460B (es) Composiciones de yodo.
NI201500140A (es) Compuestos y composiciones terapéuticos
GT201600123A (es) Inhibidores de syk
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
CR20160229A (es) Inhibidires de bromodominio
CL2021001395A1 (es) Compuestos derivados de panteteínas cíclicas; composición farmacéutica que los comprende; y su uso para aumentar las concentraciones de acetil-coa, para el tratamiento de cáncer, enfermedad inflamatoria, enfermedad neurodegenerativa, esclerosis múltiple, entre otras enfermedades.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX2020004785A (es) Proceso para preparar tapinarof.
MX2018004295A (es) Compuestos, composiciones farmáceuticas y métodos de uso de agonistas de ppar.
CL2019003213A1 (es) Compuestos plaguicidas bicíclicos.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos